FDA Approves <em>Simponi</em> For Ulcerative Colitis

FDA Approves Simponi For Ulcerative Colitis

16 May 2013

• By Paul Bonanos

J&J received approval to market a second TNF inhibitor to treat the bowel disorder. The authorization comes as Simponi’s increasing sales point toward blockbuster status.

Johnson & Johnson’s Simponi (golimumab) became the latest autoimmune drug FDA has approved for ulcerative colitis, giving the drug additional momentum on its path to becoming a blockbuster.

The inhibitor of tumor necrosis factor is J&J’s second drug approved for the disorder, alongside top seller Remicade (infliximab). Both...